{"disease":{"id":"metastatic-biliary-tract-cancer","name":"metastatic biliary tract cancer"},"drugs":{"marketed":[{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic biliary tract cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05489211","title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":454,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06792435","title":"XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Evopoint Biosciences Inc.","has_results":false},{"nct_id":"NCT03524508","title":"Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":178,"lead_sponsor_name":"Changhoon Yoo","has_results":false},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT05733000","title":"CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":94,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT03044587","title":"Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT06893380","title":"Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":61,"lead_sponsor_name":"CHA University","has_results":false},{"nct_id":"NCT06548412","title":"CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07107750","title":"Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT05742750","title":"A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":48,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05749900","title":"First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT07530445","title":"Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04722133","title":"Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT06282120","title":"Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03082053","title":"A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"ASLAN Pharmaceuticals","has_results":false},{"nct_id":"NCT03337087","title":"Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true}],"total":16},"guidelines":[{"drug_id":"durvalumab","guideline_body":"FDA label","recommendation":"IMFINZI in combination with gemcitabine and cisplatin as treatment.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"durvalumab","guideline_body":"FDA label","recommendation":"IMFINZI in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy.","line_of_therapy":"neoadjuvant/adjuvant","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}